1MOK T S,WU Y L,THONGPRASERT S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].New England Journal of Medicine,2009,(10):947-957.doi:10.1056/NEJMoa0810699.
2ZHOU C,WU Y L,CHEN G. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(optimal,ctong-0802):a multicentre,open-label,randomised,phase 3 study[J].Lancet Oncology,2011,(08):735-742.
3FUKUOKA M,WU Y L,THONGPRASERT S. Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,open-label,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia(IPASS)[J].Journal of Clinical Oncology,2011,(21):2866-2874.doi:10.1200/JCO.2010.33.4235.
4ROSELL R,MORAN T,QUERALT C. Screening for epidermal growth factor receptor mutations in lung cancer[J].New England Journal of Medicine,2009,(10):958-967.doi:10.1056/NEJMoa0904554.
5SHOJI F,YOSHINO I,YANO T. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas[J].Cancer,2007,(12):2793-2798.
6THOMPSON J A,GRUNERT F,ZIMMERMANN W. Carcinoembryonic antigen gene family:molecular biology and clinical perspectives[J].Journal of Clinical Laboratory Analysis,1991,(05):344-366.
7ORDONEZ C,SCREATON R A,ILANTZIS C. Human carcinoembryonic antigen functions as a general inhibitor of anoikis[J].Cancer Research,2000,(13):3419-3424.
8JORISSEN R N,WALKER F,POULIOT N. Epidermal growth factor receptor:mechanisms of activation and signalling[J].Experimental Cell Research,2003,(01):31-53.
9SORDELLA R,BELL D W,HABER D A. Gefitinib-sensitizing egfr mutations in lung cancer activate anti-apoptotic pathways[J].Science,2004,(5687):1163-1167.doi:10.1126/science.1101637.
10OKAMOTO T,NAKAMURA T,IKEDA J. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J].European Journal of Cancer,2005,(09):1286-1290.doi:10.1016/j.ejca.2005.03.011.
7Hejna M,Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants[J]. J Natl Cancer Inst, 1999,91 (1): 22-36.
8Loynes JT, Zacharski LR, Rigos JR. Regression of metastatic non-small cell lung cancer with low molecular weight heparin [J]. Theromb Haemost, 2002,86 (4): 686.
9Ambrus JL,Ambrus CM, Pickern J, et al. Hematologic changes and thromboembolic complication in neoplastic disease and their relationship to metastasis[J]. J Med. 1975,6: 433-458.
10Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited[J]. Blood, 1983,62:14-31.
